Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Talazoparib Beyond BRCA (TBB) Trial
Talazoparib Beyond BRCA (TBB) Trial

Talazoparib Beyond BRCA (TBB) Trial identifier:


Study Contact Information:

The study is being conducted by researchers at Stanford University Hospital. Contact Pei Jen Chang by phone at 310-967-4339 or by email.   


Talazoparib Beyond BRCA (TBB) Trial

About the Study

The goal of the study is to evaluate the anti-cancer activity of (a type of treatment known as a ) in patients with advanced breast cancer with specific genetic mutations based on a blood, saliva, or tumor test. See the listing for additional information.

The study is open to people with advanced breast cancer. There are two cohorts both of which will receive the same treatment.  

  • Cohort A
    • triple negative breast cancer and a tumor test that shows  () based on the Myriad Assay, or
  • Cohort B
    • an inherited mutation or a mutation in their tumor in one of the following genes:
      • MRE11
      • ATR
      • Fanconi anemia complementation group of genes (FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL)

This study is not open to people with a or mutation. 

Type of Study

This is an , single-arm study.

  • The study has one arm. This means that all patients in the study will receive the same treatment,

What the Study Entails

  • Patients receive 1 mg by mouth daily.

Study Lead Investigator

Melinda Telli, MD: Stanford University Hospital

This Study is Open To:

Patients with advanced breast cancer who:

  • do not have an inherited or mutation based on full sequencing and comprehensive rearrangement testing at an external reference laboratory (Myriad Genetics); patients with variants of unknown significance will be eligible
  • have measurable disease 
  • have progressed on at least 1 chemotherapy regimen for treatment of advanced breast cancer; there is no upper limit on the number of prior therapies


  •   and an score >= 42 on the Myriad Assay as assessed on a tumor biopsy sample.
    • note: in the case that obtaining an adequate tumor biopsy is not possible, we will assess the score from the primary breast tumor


  • histologically confirmed HER2-negative breast cancer
  • deleterious germline (inherited) or (tumor) mutation implicated in the () pathway, (excluding or ), based on germline multiplex gene testing or direct tumor next generation sequencing. Genes of interest include:
    • , , , , , , , , , , MRE11, ATR, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, plus other HR-related genes at the discretion of the primary investigators.
This Study is Not Open To:
  • Any patient with a in or
  • Prior treatment with a platinum agent (i.e. cisplatin or carboplatin)
  • Prior treatment with a
  • Non-measurable disease only
  • Pregnant or nursing patients
  • Any anti-cancer therapy within the past 21 days of the first day of treatment
  • Brain or central nervous system (CNS) metastases that are progressive or symptomatic, have not been previously resected or irradiated, or are the only site of measurable disease
  • Other malignancy that is either active or for which patient has received treatment in the last five years excluding non-melanoma skin cancer and carcinoma in situ of the cervix
  • Use of any investigational product (IP) or investigational medical device within 28 days before day 1 of study drug
  • Major surgery requiring a prolonged hospitalization or recovery within 21 days before day 1 of study drug